CD19 and acute lymphoblastic leukemia: Relapsed ALL is challenging to treat, but chimeric antigen receptor-modified T cells targeting CD19 offer a potential solution by overcoming the limitations of conventional therapies and inducing remission in patients with refractory disease [7].